Maternal antenatal methylxanthine (including caffeine) treatment for improving preterm outcomes

Charles Christoph C. Roehr; Rupjani Banerjee; Ana Alarcon-Allen; Eugene Dempsey

doi:10.1002/14651858.CD013275

Maternal antenatal methylxanthine (including caffeine) treatment for improving preterm outcomes

Charles Christoph C. Roehr
, Rupjani Banerjee
, Ana Alarcon-Allen
, Eugene Dempsey

Research output: Contribution to journal › Article › peer-review

Abstract

To review and summarise the existing evidence of the relationship between maternal methylxanthine (including caffeine) consumption (or by any other method of administration) versus no intervention, placebo or a different methylxanthine, before birth with the intention to influence outcomes in preterm newborns, with particular focus on cardiorespiratory adaptation at birth and long-term neurodevelopmental outcomes.

Original language	English
Article number	CD013275
Journal	Cochrane Database of Systematic Reviews
Volume	2019
Issue number	2
DOIs	https://doi.org/10.1002/14651858.CD013275
Publication status	Published - 25 Feb 2019
Externally published	Yes

Access to Document

10.1002/14651858.CD013275

Cite this

@article{1b7a6c78be704c1994c9f29822d6e1d8,

title = "Maternal antenatal methylxanthine (including caffeine) treatment for improving preterm outcomes",

abstract = "To review and summarise the existing evidence of the relationship between maternal methylxanthine (including caffeine) consumption (or by any other method of administration) versus no intervention, placebo or a different methylxanthine, before birth with the intention to influence outcomes in preterm newborns, with particular focus on cardiorespiratory adaptation at birth and long-term neurodevelopmental outcomes.",

author = "Roehr, \{Charles Christoph C.\} and Rupjani Banerjee and Ana Alarcon-Allen and Eugene Dempsey",

note = "Publisher Copyright: {\textcopyright} 2019 The Cochrane Collaboration. Published by John Wiley \& Sons, Ltd.",

year = "2019",

month = feb,

day = "25",

doi = "10.1002/14651858.CD013275",

language = "English",

volume = "2019",

journal = "Cochrane Database of Systematic Reviews",

issn = "1469-493X",

publisher = "John Wiley and Sons Ltd",

number = "2",

}

TY - JOUR

T1 - Maternal antenatal methylxanthine (including caffeine) treatment for improving preterm outcomes

AU - Roehr, Charles Christoph C.

AU - Banerjee, Rupjani

AU - Alarcon-Allen, Ana

AU - Dempsey, Eugene

PY - 2019/2/25

Y1 - 2019/2/25

N2 - To review and summarise the existing evidence of the relationship between maternal methylxanthine (including caffeine) consumption (or by any other method of administration) versus no intervention, placebo or a different methylxanthine, before birth with the intention to influence outcomes in preterm newborns, with particular focus on cardiorespiratory adaptation at birth and long-term neurodevelopmental outcomes.

AB - To review and summarise the existing evidence of the relationship between maternal methylxanthine (including caffeine) consumption (or by any other method of administration) versus no intervention, placebo or a different methylxanthine, before birth with the intention to influence outcomes in preterm newborns, with particular focus on cardiorespiratory adaptation at birth and long-term neurodevelopmental outcomes.

UR - https://www.scopus.com/pages/publications/85062373825

U2 - 10.1002/14651858.CD013275

DO - 10.1002/14651858.CD013275

M3 - Article

AN - SCOPUS:85062373825

SN - 1469-493X

VL - 2019

JO - Cochrane Database of Systematic Reviews

JF - Cochrane Database of Systematic Reviews

IS - 2

M1 - CD013275

ER -

Maternal antenatal methylxanthine (including caffeine) treatment for improving preterm outcomes

Abstract

Access to Document

Other files and links

Fingerprint

Cite this